These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 17312292)

  • 21. Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment.
    Sharvadze LG; Gogichaishvili ShSh; Sakandelidze TsG; Zhamutashvili MT; Chkhartishvili NI
    Georgian Med News; 2009 Jan; (166):61-4. PubMed ID: 19202222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inter-laboratory comparison of qualitative and quantitative detection of hepatitis C (HCV) virus RNA in diagnostic virology: a multicentre study (MS) in Italy.
    Mancini C; Pisani G; Azzi A; Luisa Zerbini M; Gentili G; Mario Bisso G;
    J Clin Virol; 2004 Aug; 30(4):313-9. PubMed ID: 15163420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon.
    Trabaud MA; Bailly F; Si-Ahmed SN; Chevallier P; Sepetjan M; Colucci G; Trépo C
    J Med Virol; 1997 May; 52(1):105-12. PubMed ID: 9131466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical and virological response of chronic hepatitis C after treatment with interferon-alpha for 6 or 12 months: predictors of sustained remission.
    Papatheodoridis GV; Katsoulidou A; Touloumi G; Delladetsima JK; Hatzakis A; Tassopoulos NC
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):469-75. PubMed ID: 8804876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.
    Su PY; Yen HH; Hsu YC; Wu SS; Kor CT; Su WW
    Kaohsiung J Med Sci; 2016 Jul; 32(7):381-6. PubMed ID: 27450028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
    Ferenci P; Laferl H; Scherzer TM; Gschwantler M; Maieron A; Brunner H; Stauber R; Bischof M; Bauer B; Datz C; Löschenberger K; Formann E; Staufer K; Steindl-Munda P;
    Gastroenterology; 2008 Aug; 135(2):451-8. PubMed ID: 18503773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
    Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic tests for hepatitis C.
    Gretch DR
    Hepatology; 1997 Sep; 26(3 Suppl 1):43S-47S. PubMed ID: 9305663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.
    Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M; Conway B; Robaeys G; Swan T; Cloherty G; Marks P; Grebely J; Dore GJ; Applegate TL
    J Clin Virol; 2017 Jul; 92():32-38. PubMed ID: 28521211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA.
    Shiratori Y; Yokosuka O; Nakata R; Ihori M; Hirota K; Katamoto T; Unuma T; Okano K; Ikeda Y; Hirano M; Kawase T; Takano S; Matsumoto K; Ohashi Y; Omata M
    Hepatology; 1999 May; 29(5):1573-80. PubMed ID: 10216145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations.
    Koppelman MH; Assal A; Chudy M; Torres P; de Villaescusa RG; Reesink HW; Lelie PN; Cuypers HT
    Transfusion; 2005 Aug; 45(8):1258-66. PubMed ID: 16078910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the molecular diagnosis of hepatitis C and their clinical implications.
    Germer JJ; Zein NN
    Mayo Clin Proc; 2001 Sep; 76(9):911-20. PubMed ID: 11560302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tests and screening strategies for the diagnosis of hepatitis C.
    Carey W
    Cleve Clin J Med; 2003 Sep; 70 Suppl 4():S7-13. PubMed ID: 14558640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
    Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical performance of the VERIS HCV assay for hepatitis C virus RNA quantification.
    Izquierdo L; Prégermain C; Hottelet C; Decombe G; Roque-Afonso AM
    J Clin Virol; 2017 Aug; 93():1-7. PubMed ID: 28550721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Tabernilla A; Grandal M; Pernas B; Castro-Iglesias A; Rodríguez-Osorio I; Mena A; Delgado M; Cid P; Pedreira JD; Poveda E
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):781-785. PubMed ID: 28410351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1.
    Buti M; Casado MA; Fosbrook L; Esteban R
    Pharmacoeconomics; 2005; 23(10):1043-55. PubMed ID: 16235977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hepatitis C virus. Virological diagnosis].
    Lunel F; Pawlotsky JM
    Pathol Biol (Paris); 1995 Oct; 43(8):681-90. PubMed ID: 8745590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.